Drug Profile
Research programme: methylthioadenosine - Digna/Avadel
Latest Information Update: 09 Jan 2017
Price :
$50
*
At a glance
- Originator Digna Biotech
- Developer Digna Biotech; Flamel Technologies
- Class Analgesics; Anti-inflammatories; Nucleosides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals
- 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in France (PO)
- 28 Jun 2011 Preclinical trials in Multiple sclerosis in France (PO)